Ocugen (OCGN) Expected to Release Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is anticipated to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Ocugen to post earnings of ($0.06) per share and revenue of $1.32 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.89 million. On average, analysts expect Ocugen to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Ocugen Stock Performance

NASDAQ OCGN opened at $0.70 on Monday. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 4.17. Ocugen has a 52 week low of $0.69 and a 52 week high of $2.73. The stock has a market capitalization of $238.29 million, a PE ratio of -2.70 and a beta of 2.05. The firm has a 50 day moving average of $1.03 and a two-hundred day moving average of $1.43.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen lowered Ocugen from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Insider Activity at Ocugen

In other news, CEO Shankar Musunuri sold 57,264 shares of the business’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $0.95, for a total value of $54,400.80. Following the completion of the sale, the chief executive officer directly owned 1,030,771 shares of the company’s stock, valued at approximately $979,232.45. The trade was a 5.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,051,982 shares of company stock worth $1,088,801 in the last 90 days. 3.95% of the stock is currently owned by insiders.

Ocugen Company Profile

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company’s programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen’s pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.